Amgen 2Q Revenues: $3.7 billion (+3%) 2Q Earnings: $1 billion (earnings were $14 million in 2Q2006) YTD Revenues: $7.4 billion (+9%) YTD Earnings: $2.1 billion (+110%) Comments: Worldwide sales of Aranesp were down 10% to $949 million, driven by a decline in U.S. demand. Sales of Epogen increased 2% to $624 million in the quarter. Combined worldwide sales of Neulasta and Neupogen increased 4% to $1 billion. Sales of Enbrel were up 14% to $823 million. R&D expenses increa...